Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

30,000 blood samples could revolutionize rapid disease testing

NCT ID NCT07378514

Knowledge-focused Sponsor: LumiraDx UK Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allows doctors to test patients right at their bedside. The goal is to make monitoring health conditions quicker and easier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to faster, easier diagnostic tests that doctors can use right at the patient's bedside.
What could go wrong
This is a sample collection study, not a treatment trial. It is early-stage research focused on developing tests, so there is no direct benefit to participants and no guarantee the tests will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

UK-based adults presenting to a study site and meeting the eligibility criteria. There are no demographic requirements for this study

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Willing to comply with study procedures. 3. The participant must present as one of the following cohorts (primary presenting condition): * Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events) * Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders) * Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome) * Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders) * Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks) * Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2) * Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia ) * Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders). Inclusion Criteria for Cohorts A, B, C, D, E, G, and H: 1\. Participants ≥ 18 years of age Inclusion Criteria for Cohort F (Diabetes Cohort): 1\. Participants ≥ 16 years old Exclusion Criteria: 1. Subjects deemed inappropriate for the study by the Principal Investigator. 2. Participants who have previously been enrolled in the EVOLVE study in the past 60 days. Exclusion Criteria for Cohort E (Oral Anticoagulation Cohort): 1. Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban. 2. Subjects who have anti-phospholipid antibody syndrome (APS) 3. The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome diabetes mellitus heart disorder heart failure Hypercholesterolemia hyperlipidemia impaired renal function disease Infections infectious disease Inflammation inflammatory disease kidney disorder liver disorder prediabetes syndrome thrombotic disease type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood clots Diabetes Heart disease High cholesterol Infection and inflammatory reaction Kidney disease Liver disease Vitamin K antagonist

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.